Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tatva Chintan Pharma Chem Limited (TATVA.NS)
Vadodara, IN
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for zeolite synthesis, phase transfer catalysts, and electrolyte salts vital for supercapacitor batteries. Furthermore, the company supplies pharmaceutical active pharmaceutical ingredients (APIs), agrochemical formulations, and various other specialized chemical products, including intermediates, disinfectants, catalytic agents, and solvents. Beyond manufacturing, Tatva Chintan engages in the trading of specialty chemicals and offers quaternary compounds (quats) and bulk drug substances. The firm's clientele spans a broad spectrum of sectors, such as the automotive, petrochemical, pharmaceutical, agricultural chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrance industries. Its global reach extends to approximately 25 nations, where its products are exported. Established in 1996, Tatva Chintan Pharma Chem Limited maintains its corporate headquarters in Vadodara, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.18% | -8.48% | -6.31% | -3.16% | -14.29% | -10.82% | +31.94% | -26.51% | -48.54% | -48.54% | -48.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+32.2% ★ Q1'26: +24.4% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+636.9% ★ Q1'26: +902.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-4.6% Q1'26: -31.8% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+11.1% ★ Q1'26: +13.7% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.7% Q1'26: +5.1% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.29× Q1'26: 1.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.34B
est: 4.36B (-0.6%)
|
4.24B
est: 4.24B (+0.0%)
|
3.94B
est: 3.85B (+2.3%)
|
3.83B
est: 3.80B (+0.8%)
|
5.10B
5.08B – 5.12B
+34.2% YoY
|
6.38B
5.96B – 6.66B
+25.2% YoY
|
8.00B
7.50B – 8.28B
+25.3% YoY
|
| EBITDA |
1.08B
est: 781.51M (+38.6%)
|
676.30M
est: 759.00M (-10.9%)
|
689.34M
est: 660.13M (+4.4%)
|
342.13M
est: 651.88M (-47.5%)
|
874.59M
871.24M – 877.93M
+34.2% YoY
|
1.10B
1.02B – 1.14B
+25.2% YoY
|
1.37B
1.29B – 1.42B
+25.3% YoY
|
| EBIT |
1.00B
est: 609.31M (+64.9%)
|
584.69M
est: 591.77M (-1.2%)
|
437.83M
est: 468.79M (-6.6%)
|
65.54M
est: 462.94M (-85.8%)
|
621.09M
618.71M – 623.47M
+34.2% YoY
|
777.78M
726.15M – 811.62M
+25.2% YoY
|
974.63M
913.63M – 1.01B
+25.3% YoY
|
| Net Income |
958.74M
est: 1.02B (-5.8%)
|
454.87M
est: 553.16M (-17.8%)
|
303.54M
est: 260.59M (+16.5%)
|
57.13M
est: 88.97M (-35.8%)
|
420.54M
339.72M – 497.22M
+372.7% YoY
|
664.00M
540.40M – 947.16M
+57.9% YoY
|
875.67M
852.44M – 1.49B
+31.9% YoY
|
| SGA |
374.41M
est: 463.75M (-19.3%)
|
338.33M
est: 450.40M (-24.9%)
|
563.05M
est: 534.69M (+5.3%)
|
529.16M
est: 528.01M (+0.2%)
|
708.39M
705.68M – 711.10M
+34.2% YoY
|
887.11M
828.22M – 925.70M
+25.2% YoY
|
1.11B
1.04B – 1.15B
+25.3% YoY
|
| EPS |
44.59
est: 43.45 (+2.6%)
|
20.52
est: 23.63 (-13.1%)
|
13.26
est: 11.24 (+18.0%)
|
2.44
est: 3.87 (-36.9%)
|
18.75
14.52 – 21.26
+384.9% YoY
|
31.00
23.11 – 40.50
+65.3% YoY
|
48.90
36.45 – 63.88
+57.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 105.2K | 0.65% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 62.3K | 0.29% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 49.0K | 0.39% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 38.9K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ajaykumar Mansukhlal Patel | Whole Time Director | 17M | male |
| Chintan Nitinkumar Shah | Chairman & MD | 17M | male |
| Shekhar Rasiklal Somani | Whole Time Director | 17M | male |
| Ishwar Nayi | Company Secretary & Compliance Officer | 1M | male |
| Harish Laljibhai Patel | Head of Operations | — | male |
| Ajesh Kumar Mohanan Pillai | Chief Financial Officer | — | male |
| Ajay Rawat | Assistant Vice President of Research and Development | — | male |
| Rakeshkumar Poonia | Deputy General Manager of Commercial | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TATVA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
